A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

NCT06931028 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the medication IBI362 in adults in China who have obstructive sleep apnea and a body mass index (BMI) of 28 or higher.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 260 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-06 · est. completion 2027-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06931028 ↗

Description as written by the study sponsor.

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of IBI362 in subjects with moderate-to-severe obstructive sleep apnea (OSA) and a body mass index (BMI) ≥28 kg/m2. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 4-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Treatments tested

placebo Other

placebo administered subcutaneously (SC) once a week.
IBI362 Drug

Once-weekly injections of gradually increased doses of IBI362

Main thing measured	Change from Baseline in Apnea-Hypopnea Index (AHI)
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Sleep Apnea, Obstructive, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06931028 ↗